ReviewFrontiers in pharmacology2025
Silicosis: from pathogenesis to therapeutics.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Evaluation of Serum Prolidase as a Biomarker and the Effects of Nintedanib in an Experimental Rat Model of Silicosis.Journal of clinical medicine · 2026Article
- Nrf2 Activation Alleviates Silica-Induced Toxicity in Alveolar Macrophages via Glutamine Metabolic Reprogramming.Toxics · 2026Article
- Splenic silicosis, a rare extrapulmonary manifestation of occupational silica exposure: A case report.Multidisciplinary respiratory medicine · 2026Article
- Silicosis, Sarcoidosis, and Silicosarcoidosis Are Overlapping Diagnoses and Difficult to Differentiate.American journal of industrial medicine · 2026Article
- The dynamic landscape of alternative splicing during silicosis progression.Respiratory research · 2026Article
- Oxidative Stress Biomarkers in Silicosis: A Systematic Review.Diseases (Basel, Switzerland) · 2026Review
- Research on the Prediction of Coal Workers' Pneumoconiosis Based on Easily Detectable Clinical Data: Machine Learning Model Development and Validation Study.JMIR medical informatics · 2026Article
- NLRP3 Inflammasome Inhibition by Xuanfei Baidu Decoction Attenuates Pulmonary Inflammation and Collagen Deposition in Silicosis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Integrated ceRNA Network Analysis in Silica-Induced Pulmonary Fibrosis and Discovery of miRNA Biomarkers.Toxics · 2026Article
- Serum KL-6 combined with immune/inflammatory biomarkers identifies complicated silicosis.BMC pulmonary medicine · 2026Article
- Tools of the trade: leveraging 3DFrontiers in pharmacology · 2026Review
- Bilateral giant progressive massive fibrosis mimicking lung cancer in a rubber factory worker: A rare presentation.Respiratory medicine case reports · 2026Article
- SSO targets CD36 to regulate lipid metabolism disorders and improve SiOCurrent research in toxicology · 2026Article
- P2X7 receptor: a potential therapeutic target for chronic respiratory diseases.Molecular and cellular biochemistry · 2026Review
- Investigating the Mechanism of Astragalus mongholicus-Mediated Treatment of Silicosis in Mice from the Perspective of Alternative Splicing.Current drug targets · 2026Article
- Characterization of engineered stone dust-induced reactive oxygen species generation and cytotoxicityJournal of toxicology and environmental health. Part A · 2026Article
- Integrating mechanical cues inFrontiers in immunology · 2026Review
- Multimodal Fusion of Chest X-Rays and Blood Biomarkers for Automated Silicosis Staging.Journal of clinical medicine · 2025Article
- The Impact of Uranium-Induced Pulmonary Fibrosis on Gut Microbiota and Related Metabolites in Rats.Metabolites · 2025Article
- Tetrandrine slows disease progression on high-resolution computed tomography and lung function decline in artificial stone-associated silicosis: a retrospective cohort study.BMC pulmonary medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silicosis is an important occupational lung disease caused by exposure to respirable crystalline silica dust particles, with the clinical manifestations from asymptomatic forms to respiratory failure. The main pathological process involves parenchymal lung injury, inflammation and lung tissue fibrosis, but the exact pathogenesis remains elusive. Until now, there have been no effective treatments for silicosis due to the complexity of pathogenesis and irreversibility of pulmonary fibrosis. In this review we attempt to summarize the advances in pathogenesis and treatment of silicosis and to explore the current understanding of the molecular mechanisms involving in the initiation and development of silicosis and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.